Day: July 30, 2021

– Harnesses breakthrough AMD RDNA™ 2 gaming architecture, offering up to 15 percent higher performance on average in 1080p gaming across a range of popular titles compared to the competition – – Powerful blend of raytracing, compute and rasterized effects pairs with AMD FidelityFX Super Resolution upscaling technology and other advanced features to bring new levels of visual fidelity and high-framerate gaming to the mainstream – SANTA CLARA, Calif., July 29, 2021 (GLOBE NEWSWIRE) — AMD (NASDAQ: AMD) today announced the AMD Radeon™ RX 6600 XT graphics card, designed to deliver the ultimate high-framerate, high-fidelity and highly responsive 1080p gaming experience. The AMD Radeon RX 6600 XT graphics card is built on breakthrough AMD RDNA™ 2 architecture, the only gaming architecture that spans from next-generation desktop PCs, laptops...

Los Angeles, CA, July 29, 2021 (GLOBE NEWSWIRE) — Draganfly Inc. (Nasdaq: DPRO) (CSE: DPRO) (FSE: 3U8) (“Draganfly” or the “Company”), a drone manufacturer and systems developer, today announced the pricing of its underwritten public offering of 5,000,000 common shares of the Company at a public offering price of US$4.00 per share, for gross proceeds of US$20,000,000, before deducting underwriting discounts and offering expenses. Closing of the offering is expected to occur on August 3, 2021, subject to the satisfaction of customary closing conditions. In addition, the underwriters have been granted a 45-day over-allotment option following the closing date to purchase up to an additional 750,000 common shares from the Company. ThinkEquity, a division of Fordham Financial Management, Inc., is acting as sole book-running manager...

CAMBRIDGE, Mass., July 29, 2021 (GLOBE NEWSWIRE) — Immuneering Corporation (Nasdaq: IMRX), a biopharmaceutical company advancing a robust pipeline of oncology and neuroscience product candidates that are designed to uniquely disrupt cellular signaling dynamics, today announced the pricing of its upsized initial public offering of 7,500,000 shares of Class A common stock at a public offering price of $15.00 per share, for total gross proceeds of $112.5 million, before deducting underwriting discounts and commissions and estimated offering expenses payable by Immuneering. All of the Class A common stock is being offered by Immuneering. The offering is expected to close on August 3, 2021, subject to customary closing conditions. In addition, Immuneering has granted the underwriters a 30-day option to purchase up to an additional 1,125,000...

ALISO VIEJO, Calif., July 29, 2021 (GLOBE NEWSWIRE) — RxSight, Inc., an ophthalmic medical device company, today announced the pricing of its initial public offering of 7,350,000 shares of common stock at a public offering price of $16.00 per share. The gross proceeds to RxSight® from the offering are expected to be $117.6 million, before deducting underwriting discounts and commissions and offering expenses. In addition, RxSight has granted the underwriters a 30-day option to purchase up to an additional 1,102,500 shares of common stock at the initial public offering price, less underwriting discounts and commissions. RxSight’s common stock is expected to begin trading on the Nasdaq Global Market on July 30, 2021, under the ticker symbol “RXST.” The offering is expected to close on August 3, 2021, subject to the satisfaction of...

Westport, CT, July 29, 2021 (GLOBE NEWSWIRE) — Williams Rowland Acquisition Corp. (the “Company”), a newly organized blank check company incorporated as a Delaware corporation and led by Co-Chief Executive Officers, David “Tiger” Williams and Jonathan Rowland, today announced the closing of its initial public offering of 20,000,000 units at an offering price of $10.00 per unit, with each unit consisting of one share of the common stock of the Company and one-half of one redeemable warrant. Each whole warrant will entitle the holder thereof to purchase one share of common stock at $11.50 per share. The Company has granted the underwriter a 45-day option to purchase up to 3,000,000 additional units at the initial public offering price to cover over-allotments, if any. The units began trading on July 27, 2021 on the New York Stock...

SHANGHAI, China, July 30, 2021 (GLOBE NEWSWIRE) — Junshi Biosciences (HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies, announced today that the National Medical Products Administration (NMPA) of China has accepted its supplemental New Drug Application (sNDA) for toripalimab in combination with platinum-containing chemotherapy as the first-line treatment for patients with locally advanced or metastatic esophageal squamous cell carcinoma (ESCC). It is the fifth NDA submitted for toripalimab in China. The supplemental NDA is based on the JUPITER-06 study (Clinicaltrials.gov identifier: NCT03829969), which is a randomized, double-blind, placebo-controlled Phase III clinical study led by Professor Ruihua Xu from Sun Yat-sen...

TORONTO, July 29, 2021 (GLOBE NEWSWIRE) — iSIGN Media Solutions Inc. (“iSIGN” or “Company”) (TSX-V: ISD) (OTC: ISDSF), a leading provider of interactive mobile proximity marketing and public security alert solutions announced that it intends to complete a non-brokered offering (“Offering”) for aggregate gross proceeds of $1.2 million. Under the terms of the Offering the Company will issue up to 24 million Units at a price of $0.05 per Unit. Each Unit consists of one Common Share of the Company (each a “Common Share” and collectively, the “Common Shares”) and one common share purchase warrant (each warrant referred to herein as a “Warrant” and collectively, the “Warrants”). Each Warrant will entitle the holder to purchase one Common Share at a price of $0.075 for a period of 24 months from the date of closing. All securities issued...